BenchSci Fast Facts

BenchSci is a world leader in AI enterprise solutions for drug discovery.

We help pharma organizations transform their R&D portfolio by developing the first objective, evidence-backed map of the underlying biology for all diseases using patented machine learning technology that is trained by scientists to extract experiment evidence from internal and external data sources.

This technology is made available to researchers through our intuitive software platform, ASCEND™. It empowers scientists and augments programs across the research pipeline, allowing our partners to increase the speed and yield of their portfolio by multiples, not percentages.

OFFICES: TORONTO, ON AND CAMBRIDGE, UK
FOUNDERS: TOM LEUNG, ELVIS WIANDA, AND LIRAN BELENZON
EMPLOYEES: 400+

BenchSci

TRAINING AI

6 YEARS

15,611,769
PAPERS ANALYZED

PLATFORM USERS

50,000+

16/20
TOP PHARMA COMPANIES

4,500
ACADEMIC RESEARCH INSTITUTIONS

INVESTORS

AFORE CAPITAL · F-PRIME · GOLDEN VENTURES · inovia · Northleaf · RADICAL VENTURES · real VENTURES · TCV

SCIENTIFIC ADVISORY BOARD (SAB) MEMBERS

Steve Hitchcock, Chief Scientific Officer Takeda
Philip Larsen, SVP and Global Head of Research Bayer
Philip Tagari, VP of Research (Therapeutic Discovery) Amgen
Mark Burfoot, Global Head of Research Procurement Novartis
Matt Truppo, Global Head of Research Platforms Sanofi